Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration: A Randomized, Multicentre, Controlled Trial
Latest Information Update: 25 Nov 2024
At a glance
- Drugs Adalimumab (Primary) ; Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Biomarker; Therapeutic Use
- Acronyms VEDIAN
Most Recent Events
- 20 Nov 2024 Status changed from not yet recruiting to recruiting.
- 24 Oct 2024 Planned initiation date changed from 1 Sep 2024 to 1 Oct 2024.
- 05 Aug 2024 Planned initiation date changed from 1 Jul 2024 to 1 Sep 2024.